Journal Article

Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus

Daniel E. Dulek, John V. Williams, C. Buddy Creech, Alynna K. Schulert, Haydar A. Frangoul, Jennifer Domm, Mark R. Denison and James D. Chappell

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 50, issue 11, pages 1493-1496
Published in print June 2010 | ISSN: 1058-4838
Published online June 2010 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/652655
Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.

Journal Article.  2588 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.